Literature DB >> 34970333

The promise and problems of metabolic-based therapies for heart failure.

Dianne M Perez1.   

Abstract

Despite standard therapies, heart failure patients have high rates of morbidity highlighting the need to develop alternative therapeutic approaches. Heart failure has been described as an energy-starved condition that is hypothesized to drive the pathological remodeling of the heart. Numerous studies have described the metabolic defects that occur when the heart fails and adaptive changes that take place to maintain the energy needed for the heart to function properly. In this review we will summarize the metabolic requirements of a normal heart and what happens during failure. We will also summarize the various metabolic therapeutic strategies that have been developed over the years to treat heart failure and their results from clinical trials.

Entities:  

Keywords:  Adrenergic receptor; Heart failure; Metabolism; Myocyte

Year:  2021        PMID: 34970333      PMCID: PMC8715677     

Source DB:  PubMed          Journal:  Interv Cardiol (Lond)        ISSN: 1755-5302


  113 in total

1.  Changes in citric acid cycle flux and anaplerosis antedate the functional decline in isolated rat hearts utilizing acetoacetate.

Authors:  R R Russell; H Taegtmeyer
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

2.  Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics.

Authors:  Mei-Ling Cheng; Chao-Hung Wang; Ming-Shi Shiao; Min-Hui Liu; Yu-Yen Huang; Cheng-Yu Huang; Chun-Tai Mao; Jui-Fen Lin; Hung-Yao Ho; Ning-I Yang
Journal:  J Am Coll Cardiol       Date:  2015-04-21       Impact factor: 24.094

3.  Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.

Authors:  Kenneth Dickstein; John Kjekshus
Journal:  Lancet       Date:  2002-09-07       Impact factor: 79.321

4.  On the inability of ketone bodies to serve as the only energy providing substrate for rat heart at physiological work load.

Authors:  H Taegtmeyer
Journal:  Basic Res Cardiol       Date:  1983 Jul-Aug       Impact factor: 17.165

5.  Hemodynamic and energetic comparison of bucindolol and metoprolol for the treatment of congestive heart failure.

Authors:  C M Heesch; L Marcoux; B Hatfield; E J Eichhorn
Journal:  Am J Cardiol       Date:  1995-02-15       Impact factor: 2.778

6.  Influence of mildronat on left ventricular systolic, diastolic functional parameters, pulmonary arterial flow and systolic dyssynchrony in patients with congestive heart failure.

Authors:  M D Tsverava
Journal:  Georgian Med News       Date:  2013-05

7.  The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense.

Authors:  Julie L Horton; Michael T Davidson; Clara Kurishima; Rick B Vega; Jeffery C Powers; Timothy R Matsuura; Christopher Petucci; E Douglas Lewandowski; Peter A Crawford; Deborah M Muoio; Fabio A Recchia; Daniel P Kelly
Journal:  JCI Insight       Date:  2019-02-21

8.  Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers.

Authors:  Sowmya Venkatasubramanian; Radzi Mohd Noh; Shruti Daga; Jeremy P Langrish; Nikhil V Joshi; Nicholas L Mills; Ethan Hoffmann; Eric W Jacobson; George P Vlasuk; Brian R Waterhouse; Ninian N Lang; David E Newby
Journal:  J Am Heart Assoc       Date:  2013-06-14       Impact factor: 5.501

Review 9.  Treating oxidative stress in heart failure: past, present and future.

Authors:  Atze van der Pol; Wiek H van Gilst; Adriaan A Voors; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2018-10-19       Impact factor: 15.534

10.  A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress in vivo and in vitro.

Authors:  Yu-Jie Xing; Biao-Hu Liu; Shu-Jun Wan; Yi Cheng; Si-Min Zhou; Yue Sun; Xin-Ming Yao; Qiang Hua; Xiang-Jian Meng; Jin-Han Cheng; Min Zhong; Yan Zhang; Kun Lv; Xiang Kong
Journal:  Front Pharmacol       Date:  2021-07-12       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.